References
1 A. Jemal, R. Siegel and J. Xu et al., Cancer statistics, 2010, CA Cancer J Clin 60 (2010), pp. 277–300. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (543)
2 R.A. Kyle, M.A. Gertz and T.E. Witzig et al., Review of 1027 patients with newly diagnosed multiple myeloma, Mayo Clin Proc 78 (1) (2003), pp. 21–33. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (396)
3 A. Corso, P. Zappasodi and C. Pascutto et al., Urinary proteins in multiple myeloma: correlation with clinical parameters and diagnostic implications, Ann Hematol 82 (8) (2003), pp. 487–491. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (9)
4 V. Eleutherakis-Papaiakovou, A. Bamias and D. Gika et al., Renal failure in multiple myeloma: incidence, correlations, and prognostic significance, Leuk Lymphoma 48 (2) (2007), pp. 337–341. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (35)
5 L.S. Rosen, D. Gordon and M. Kaminski et al., Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial, Cancer J 7 (5) (2001), pp. 377–387. View Record in Scopus | Cited By in Scopus (461)
6 L.S. Rosen, D. Gordon and M. Kaminski et al., Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial, Cancer 98 (8) (2003), pp. 1735–1744. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (329)
7 , Zometa (package insert), Novartis Pharmaceuticals, Corporation, East Hanover, NJ (2008).
8 P. Major, A. Lortholary and J. Han et al., Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials, J Clin Oncol 19 (2) (2001), pp. 558–567. View Record in Scopus | Cited By in Scopus (325)
9 T. Chen, J. Berenson and R. Vescio et al., Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases, J Clin Pharmacol 42 (11) (2002), pp. 1228–1236. View Record in Scopus | Cited By in Scopus (139)
10 T. Pfister, E. Atzpodien and F. Bauss, The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats, Toxicology 191 (2003), pp. 159–167. Article | PDF (320 K) | View Record in Scopus | Cited By in Scopus (48)
11 T. Pfister, E. Aztpodien, B. Bohrmann and F. Bauss, Acute renal effects of intravenous bisphosphonates in the rat, Basic Clin Pharmacol Toxicol 97 (2005), pp. 374–381. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (17)
12 F. Saad, D.M. Gleason and R. Murray et al., A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst 94 (19) (2002), pp. 1458–1468. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (650)
13 S. Kautiainen, S. Luurila, P. Ylitalo and R. Ylitalo, Transformation of bisphosphonates into insoluble material in human blood in vitro, Methods Find Exp Clin Pharmacol 20 (4) (1998), pp. 289–295. View Record in Scopus | Cited By in Scopus (5)
14 L.S. Rosen, D. Gordon and S. Tchekmedyian et al., Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group, J Clin Oncol 21 (16) (2003), pp. 3150–3157. Full Text via CrossRef | View Record in Scopus | Cited By in Scopus (251)
15 M.A. Hussein, Multiple myeloma: most common end-organ damage and management, J Natl Compr Canc Netw 5 (2) (2007), pp. 170–178. View Record in Scopus | Cited By in Scopus (4)
Appendix
The following ZMAX Trial principal investigators participated in this study: Bart Barlogie, MD, Myeloma Institute For Research and Therapy; James Berenson, MD, Oncotherapeutics; Robert Bloom, MD, Providence Cancer Center, Clinical Trials Department; Ralph Boccia, MD, Center for Cancer and Blood Disorders; Donald Brooks, MD, Arizona Clinical Research Center, Inc.; Robert Brouillard, MD, Robert P. Brouillard, MD, and Delvyn Case, MD, Maine Center for Cancer Medicine and Blood Disorders, Pharmacy; Veena Charu, MD, Pacific Cancer Medical Center; Naveed Chowhan, MD, Cancer Care Center, Inc; Robert Collins, MD, University of Texas Southwestern Medical Center at Dallas; Thomas Cosgriff, MD, Hematology and Oncology Specialists, LLC; Jose Cruz, MD, Joe Arrington Cancer Research and Treatment Center; Surrinder Dang, MD, Oncology Specialties; Sheldon Davidson, MD, North Valley H/O; Tracy Dobbs, MD, Baptist Regional Cancer Center; Luke Dreisbach, MD, Desert Hematology Oncology Medical Group; Isaac Esseesse, MD, Hematology Oncology Associates of Central Brevard, Laboratory; Mark Fesen, MD, Hutchinson Clinic, PA; George Geils, Jr., MD, Charleston Hematology Oncology Associates, PA; Michael Greenhawt, MD, South Florida Oncology-Hematology; Manuel Guerra, MD, ORA; Rita Gupta, MD, Oncology-Hematology Associates, PA; Vicram Gupta, MD, Saint Joseph Oncology; Alexandre Hageboutros, MD, Cancer Institute of New Jersey at Cooper Hospital; Vincent Hansen, MD, Utah Hematology Oncology; David Henry, MD, Pennsylvania Oncology Hematology Associates; Benjamin Himpler, MD, Syracuse Hematology/Oncology PC; Winston Ho, MD, Hematology/Oncology Group of Orange County; William Horvath, MD, Haematology Oncology Associates of Ohio and Michigan, PC; Paul Hyman, MD, Hematology Oncology Associates of Western Suffolk; Min Kang, MD, Western Washington Oncology; Mark Keaton, MD, Augusta Oncology Associates, PC; Howard Kesselheim, MD, The Center for Cancer and Hematologic Disease; Kapisthalam Kumar, MD, Pasco Hernando Oncology Associates, PA; Edward Lee, MD, Maryland Oncology-Hematology, PA; André Liem, MD, Pacific Shore Medical Group; Timothy Lopez, MD, New Mexico Cancer Care Associates, Cancer Institute of New Mexico; Paul Michael, MD, Comprehensive Cancer Centers of Nevada; Michael Milder, MD, Swedish Cancer Institute; Barry Mirtsching, MD, Center for Oncology Research & Treatment, PA; Ruben Niesvizky, MD, New York Presbyterian Hospital; Jorge Otoya, MD, Osceola Cancer Center; Joseph Pascuzzo, MD, California Oncology of the Central Valley; Ravi Patel, MD, Comprehensive Blood and Cancer Center Lab; Allen Patton, MD, Hematology Oncology Associates, PA; Kelly Pendergrass, MD, Kansas City Cancer Center, LLC; Anthony Phillips, MD, Fox Valley Hematolgy Oncology, SC; Robert Raju, MD, Dayton Oncology and Hematology, PA; Harry Ramsey, MD, Berks Hematology Oncology Associates; Ritesh Rathore, MD, Roger Williams Hospital Medical Center; Phillip Reid, MD, Central Jersey Oncology Center; Robert Robles, MD, Bay Area Cancer Research Group, LLC; Stephen Rosenoff, MD, Oncology and Hematology Associates of Southwest Virginia, Inc; Martin Rubenstein, MD, Southbay Oncology Hematology Partners; Mansoor Saleh, MD, Georgia Cancer Specialists; Sundaresan Sambandam, MD, Hematology and Oncology Associates of RI; Mukund Shah, MD, Antelope Valley Cancer Center; David Siegel, MD, Hackensack University Medical Center; Nelida Sjak-Shie, MD, The Center for Cancer Care and Research; Michael Stone, MD, Greeley Medical Clinic; Stefano Tarantolo, MD, Nebraska Methodist Hospital; Joseph Volk, MD, Palo Verde Hematology Oncology, Ltd; Mitchell Weisberg, MD, MetCare Oncology; Ann Wierman, MD, Nevada Cancer Center; Donald Woytowitz, Jr., MD, Florida Cancer Specialists; Peter Yu, MD, Camino Medical Group.